Raymond James Financial’s Kazia Therapeutics KZIA Stock Holding History

Raymond James Financial’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117K	Buy	+15,749	New	+$110K	﹤0.01%	5004

Other funds holding KZIA

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raymond James Financial's KZIA Position: Q1 2026 in Review

Raymond James Financial opened a new position in Kazia Therapeutics (KZIA) in Q1 2026: 15,749 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #5004 among its holdings.

23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

Raymond James Financial held 15,749 shares of Kazia Therapeutics worth $117K as of Q1 2026.
Kazia Therapeutics was a new Raymond James Financial position in Q1 2026.
Kazia Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5004 holding.
23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.